MYCN and neuroblastoma: Considering that increased expression of MYCN is positively associated with CDK4 expression, targeting CDK, which is responsible for the transition from G0/1 into the S phase, could theoretically be beneficial for putting the “brakes” on the aberrant proliferation in patients with MYCN-amplified neuroblastoma (Figure 1).